Literature DB >> 15005347

Successful treatment of mu-heavy chain disease with fludarabine monophosphate: a case report.

Machi Yanai1, Akinori Maeda, Naoko Watanabe, Naoshi Sugimoto, Akiko Matsushita, Kenichi Nagai, Tatsuo Oida, Takayuki Takahashi.   

Abstract

Heavy chain diseases (HCD) are monoclonal lymphoproliferative disorders of B-cells characterized by the synthesis of truncated heavy chains without associated light chains. In patients with mu-HCD, which is a very rare form of HCD, neoplastic cells produce immunoglobulin M heavy chain. The prognosis for patients with mu-HCD is poor, and there is no specific treatment for mu-HCD. In this report, we present a patient with mu-HCD accompanied by splenomegaly and thrombocytopenia. We treated this patient with the fludarabine monophosphate therapy we use for patients with B-cell chronic lymphocytic leukemia. After 5 courses of fludarabine monophosphate treatment, the splenomegaly and thrombocytopenia improved. Fludarabine monophosphate therapy may be a new strategy to improve the prognosis of patients with mu-HCD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15005347     DOI: 10.1532/ijh97.03053

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

1.  mu-chain disease. Report of two new cases.

Authors:  J C Brouet; M Seligmann; F Danon; D Belpomme; J M Fine
Journal:  Arch Intern Med       Date:  1979-06

2.  A case of mu heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test.

Authors:  M Witzens; G Egerer; D Stahl; E Werle; H Goldschmidt; R Haas
Journal:  Ann Hematol       Date:  1998-11       Impact factor: 3.673

3.  MU-chain disease in an African patient.

Authors:  J Bonhomme; M Seligmann; C Mihaesco; J P Clauvel; F Danon; J C Brouet; P Bouvry; J Martine; M Clerc
Journal:  Blood       Date:  1974-04       Impact factor: 22.113

4.  Mu-chain disease.

Authors:  S L Lee; F Rosner; W Ruberman; S Glasberg
Journal:  Ann Intern Med       Date:  1971-09       Impact factor: 25.391

5.  A new case of mu heavy chain disease: clinical and immunochemical studies.

Authors:  F Dammacco; L Bonomo; E C Franklin
Journal:  Blood       Date:  1974-05       Impact factor: 22.113

6.  Rocket immunoselection for detection of heavy-chain diseases.

Authors:  D S Gale; J M Versey; J R Hobbs
Journal:  Clin Chem       Date:  1974-10       Impact factor: 8.327

7.  H chain fragment and monoclonal IgA in a lymphoproliferative disorder.

Authors:  A S Josephson; A Nicastri; E Price; L Biro
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

8.  mu-chain disease in a case of chronic lymphocytic leukaemia and malignant histiocytoma. I. Clinical aspects.

Authors:  V Jonsson; A Videbek; N H Axelsen; M Harboe
Journal:  Scand J Haematol       Date:  1976-03

9.  A case of mu-heavy chain disease: combined features of mu-chain disease and macroglobulinemia.

Authors:  T Iwasaki; T Hamano; K Kobayashi; E Kakishita
Journal:  Int J Hematol       Date:  1997-10       Impact factor: 2.490

Review 10.  New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia.

Authors:  C M Wendtner; B Schmitt; M Bergmann; T Röhnisch; R Buhmann; M Hallek
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.319

View more
  2 in total

1.  Multiple extranodal tumors in mu-heavy chain disease.

Authors:  Akinori Maeda; Minako Mori; Satoko Torii; Yuya Nagai; Katsuhiro Togami; Haruyuki Fujita; Masayuki Kurata; Akiko Matsushita; Kenichi Nagai; Yukihiro Imai; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

Review 2.  Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update.

Authors:  Roberto Ria; Franco Dammacco; Angelo Vacca
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.